Member Info for MR.Spacetomato

EricHorseman,

To be honest I wasn't too sure Cytiva has been appointed as one of the manufacturers, like BBI. I thought Cytiva was only the developer but I may be wrong and indeed it would be silly not to use the Americans to manufacture it in scale for the market.

Damn, need to go back into research on that.

ST

xxxyyyzzz, great post.

We have so many things going on for avacta that I expect multiple rnss shortly. It is a waiting game for us.

Good luck mate.

Hello, Richob.

Actually, I am floating somewhere in the north sea, at the moment, with nothing in site but the stars and the odd lost penguin to keep company. Don't ask me how he turned up here, but again, you are talking to a football!

Anyway, off again to where the current is taking me.

Good luck and speak soon when I get some signal.

Wilson

And investment advice is Not investment advice

Sorry, typed too fast:

PCT is PCR
Remdisivir is Remdesivir
Nasalpharingal is Nasopharyngeal

St

TedB,

Hi. My opinion is the following: as much as there is a shift in the testing field, ie, from Nasalpharingal pct to LFA saliva quick test, now there seems to be a shift from injection to inhalation treatments. See Gilead shift to inhaled remdisivir.

In my opinion inhaled treatment is the way forward, hence my bet is on Gilead approaching SNG for combo inhaled therapy. Our CEO already said they would start talking to the FDA a while. I see smoke but it is my opinion and investment advice.

ST

MrsKOB,

Do you know if Norwegian air flies to New Zealand? I just splashed £1,000 on them already counting on AVCT tests. :0)

Sorry for the off topic.

Wilson

xxxyyyzzz,

I take your point, but could we consider that the appointment of Neil Bell as Chief Development Officer implies also that AS would take onboard his views on possibly have a Nasdaq listing, or even a move out of AIM?

As being able to have their fingers on so many pies at the same time shows avacta is able to expand rapidly their projects.

ST

..sorry, I have only upward thoughts with SNG.

....and the fact that interferon beta was kept in the solidarity WHO trial is a very good sign for me.

ST

Sparkle1,

Your post Drug Combos had to do with WHO solidarity trial, ie, the testing of 4 drugs either on their own or in combination. I replied on this post only and highlighted the fact that hydroxychloroquine and liponavir/ritonavir were abandoned, leaving only remdisivir and interferon beta in this solidarity trial.

ST

Lenin, good morning.

Well, well, I just bought me some shares here (just a grand) at 12p.

My point is the 5-10 min quick lateral flow assays will be coming to the markets in a month or so. THAT is where my signal is. So I position myself today on the cheapest airline share in the market at 1.5 kroner.

Once the shorters realise that this little airline (5th in the world) will go somewhere.

The clock is ticking now...tick-tock

Good luck to holders.

ST

Sparkle1 - in early July, both hydroxichloroquine and liponavir/ritonavir arms were dumped as proved non efficient. Only remaining contenders are remdesivir and interferon beta.

ST

Nasdaq listing?

Christ, I am more interested in getting phase I clinical trials on the way! This lad has all the expert knowledge that we need to build and lead his team so we bring the precision technology into full steam. That is worth everything we got.

Great news I even forgot about LFA bit...

ST

Link originally posted by Spike66. Thanks mate.

https://www.technologynetworks.com/diagnostics/articles/vital-lessons-for-the-diagnostics-industry-from-covid-19-338075

Vital Lessons for the Diagnostics Industry From COVID-19
ARTICLE   Aug 10, 2020 | By Emmanuel Abate, Cytiva

This section is the best bit:

"Partnership for assay development

The pandemic triggered a massive response from the diagnostic industry, where both established players and newcomers focussed their development efforts on both Polymerase Chain Reaction (PCR) based and lateral flow (also known as rapid testing) for COVID-19. Both types of diagnostic assay are complicated to develop and draw upon expertise in diverse areas such as material science, biochemistry, and virology, as well as manufacturing for scale-up. Optimizing assays for high sensitivity to detect the virus is a challenge and the accuracy of initial COVID-19 tests varied significantly.

The inconsistency in testing diagnostic performance highlighted the need for close partnership between diagnostic developers and component and material providers. Collaboration, in a spirit of co-design, would allow time to be taken to test component interactions thus reducing the risk of suboptimal component choice or scale up challenges. In the lateral flow space, that would mean that the provider of filtration materials, such as pads and nitrocellulose membranes, would work together with the assay developer. Together they could select and purify the relevant markers before selecting the membrane for optimal binding and flow...

...COVID-19 has taught me a lot: how the diagnostics industry needs to prepare for future pandemic challenges, but also what can be improved across the sector more generally. I believe vendors need to partner with developers to offer their manufacturing and design expertise to advance and accelerate the industry. In the hunt for a high-quality diagnostic, no one can do it alone".

My view on the article is that there was a time before Avacta's affimers and a time after. That it is possible together with a diagnostics partner to improve great the flow tests and that this was achieved. "Together they could select and purify the relevant markers before selecting the membrane for optimal binding and flow", which they did!

Our test looks good.

ST

This is what the FDA says in their latest announcement:

FDA Commissioner Stephen M. Hahn, M.D. “The recommendations provided today are intended to help get tests to market that are simple enough to use at home, similar to a pregnancy test. We hope that with the innovation we’ve seen in test development, we could see tests that you could buy at a drug store, SWAB YOUR NOSE or COLLECT SALIVA, run the test, and receive results within minutes at home, once these tests become available. These types of tests will be a game changer in our fight against COVID-19 and will be crucial as the nation looks toward reopening.”

Now, I have read a couple of academic articles from the Journal of infection that showed saliva as the best way to identify an asymptomatic or symptomatic case. To pick up the virus from your nose comfortably may not get the results you need and their clinical trials may lead to a failure. They are risking it in my view (good for us).

And now that we know it is nasal but saliva test that we watched on CBS it is definitely not erasure.

Come on avacta.

So, and it's not saliva anymore "Although originally intended for use with oral fluid, this test has been modified to employ an easily and comfortably self-collected lower nostril sample in order to achieve the best possible accuracy".

https://www.inquirer.com/news/spit-test-covid-coronavirus-orasure-fda-hiv--20200706.html

PL75, going back the the drawing board is good news for us then. They must be one of those who rushed things. And they wanted to charge just under $50 a test.

Good find.

It could be Orasure? They received grant from BARDA (Biomedica research development authority) USA. They already do oral self test for HIV with sensitivity of 98% and it's an antigen.

If they managed to get it so can we! There is space for everyone.

ST

In Development:

Pinpoint Science POC 15 min TBD (sensitivity) Medium (price)
Hememics Biotechnologies Consumer DIY 15 TBD Medium
Canary Health Technologies Consumer DIY 5 TBD Low
E25Bio Consumer DIY 15 TBD Low
Sona Nanotech POC 15 96% Low
Luminostics Consumer DIY 5–30 TBD Low
Nanomix Consumer DIY 10 TBD Low
Assure Tech DIY 15 “High” Low
Leadgene® SARS/SARS-CoV-2 Antigen DIY 15 TBD Low
Orasure Technologies OraQuick DIY 20 TBD Low
Avacta/Cytiva DIY 15 TBD Low
PCL Covid-19 Ag GICA POC 10 100% Medium

I took these from the Rockerfeller foundation